US FDA denies Genzyme's Clolar for acute myeloid leukaemia
This article was originally published in Scrip
Executive Summary
The US FDA has declined to approve Genzyme's oncologic agent Clolar (clofarabine) for previously untreated elderly adults with acute myeloid leukaemia (AML) absent a randomised, controlled clinical trial in this population, the company said.